All In Biotech

Drug Trial Radar · NCT01416194

Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

COHORT STUDY OF VENOUS THROMBOEMBOLISM AND OTHER CLINICAL ENDPOINTS AMONG OSTEOPOROTIC WOMEN PRESCRIBED BAZEDOXIFENE, BISPHOSPHONATES OR RALOXIFENE IN EUROPE

Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10,497

Actual

Start

Jul 25, 2011

Primary completion

Apr 30, 2019

Study completion Apr 30, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 12, 2011

More drug trials from this sponsor

Design

Study type
Observational
Who can join
Female only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This observational cohort study is being conducted to further characterize selected adverse events of interest among a patient population with osteoporosis who are prescribed bazedoxifene, raloxifene, or a bisphosphonate in usual clinical care outside of a randomized clinical trial setting. The study will compare the rates of the selected clinical events among the three treatment groups.

Conditions

  • Osteoporosis, Postmenopausal

Interventions

  • BazedoxifeneDrug

    Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.

  • BisphosphonateDrug

    Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.

  • RaloxifeneDrug

    Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Incidence of Venous Thromboembolism (VTE)Time frame: Up to a maximum of follow-up period of 92.1 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.